ClinicalTrials.gg
Not yet recruitingNCT07858409Updated Oct 5, 2026

Phoenixin and Pain in Pediatric Burn Patients

An observational study in Children, Acute Pain and Burn Pain, sponsored by Ankara City Hospital Bilkent. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 1 Month to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Ankara City Hospital Bilkent · Observational

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
87
Ages
1 Month to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 158 studies in Acute Pain with a site in Turkey — 23 open to participants now, 26 under way, none of them phase 3. Acute Pain · Turkey.

Planned enrollment
12th of 23
87 · median 87
Started
2026
with 14 others
Observational
23 of 158
4 open now
Primary completion
2027-05
later than 22 of 25 live
Registered
158th of 158
by date
Lead sponsor
5 of 158
Ankara City Hospital Bilkent

Among the 158 studies in Acute Pain with a site in Turkey, this one is the 12th largest by planned enrollment of the 23 observational ones that give a count, is one of 15 that started in 2026, is one of 23 observational ones, reaches primary completion later than 22 of the 25 other live ones, and was the 158th registered.

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

23 of the 158 studies in Acute Pain with a site in Turkey are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 1 Month to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Acute Pain with a site in Turkey, or all of them as a file.
02

Study summary

This prospective, controlled, observational study aims to investigate the relationship between phoenixin (PNX) levels and pain in pediatric burn patients. A total of 87 prepubertal children under 18 years of age will be included and evaluated in three independent groups: 29 children with second-degree burns in the acute burn period and experiencing pain at the time of assessment, 29 children with a history of burn injury at least three months previously who have completed the acute burn and procedural pain period, and 29 age-similar healthy controls without a history of burns or acute pain.

Blood and urine samples will be collected from all participants, and PNX levels will be measured using an enzyme-linked immunosorbent assay (ELISA). Pain intensity will be assessed using age-appropriate validated pain assessment tools, including the Face, Legs, Activity, Cry, Consolability (FLACC) scale and the Visual Analog Scale (VAS), as appropriate. In the burn groups, burn characteristics, including total body surface area (TBSA), will also be recorded.

The study will compare blood and urine PNX levels among the acute burn, chronic burn, and healthy control groups and will evaluate the relationship between PNX levels and clinical pain intensity in children with acute burns. Secondary analyses will examine the relationships between blood and urine PNX levels and their associations with TBSA and demographic and clinical characteristics. The findings are expected to provide preliminary clinical data on the potential role of PNX as a pain-related biological marker in pediatric burn patients.

Read the detailed description

Phoenixin (PNX) is a neuropeptide with diverse physiological functions, and experimental findings suggest that it may be involved in nociceptive pathways. However, its relationship with clinical pain, particularly acute pain in pediatric burn patients, has not been well established. Pediatric burn pain is a dynamic clinical condition influenced by both the burn injury itself and repeated painful procedures, and objective biological measures that complement clinical pain assessment may contribute to a better understanding of its underlying mechanisms.

This study is designed to investigate the potential relationship between PNX levels and pain in pediatric burn patients by evaluating PNX in both blood and urine. Three clinically distinct populations will be assessed: children in the acute phase of second-degree burn injury with pain at the time of assessment, children with a history of burn injury at least three months previously who are beyond the acute burn and procedural pain period, and age-similar healthy children without acute pain or a history of burns. This design will allow PNX levels observed during acute burn-related pain to be interpreted in comparison with both the post-acute burn period and a population without burn injury or acute pain.

PNX measurements will be evaluated together with age-appropriate clinical pain scores and burn-related characteristics, including total body surface area. Blood and urine PNX levels will also be examined in relation to each other. The study is exploratory and is intended to generate preliminary clinical evidence regarding the potential role of PNX as a pain-related biological marker rather than to establish PNX as a validated diagnostic biomarker for pain.

03

Conditions studied

  • Children
  • Acute Pain
  • Burn Pain
  • Burn Degree Second

Keywords

  • Phoenixin
  • Pediatric Burns
  • Pain Biomarker
  • Burn Pain
  • PNX
04

Who can participate

Ages eligible
1 Month to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of pediatric participants prospectively recruited at Ankara Bilkent City Hospital. The acute burn group will include children with acute second-degree burn injuries who are being followed and treated in the pediatric burn intensive care unit. The chronic burn group will consist of children with a previous burn injury, with at least three months elapsed since the burn, who are evaluated during follow-up after the acute phase. The healthy control group will consist of children without a history of burn injury who are evaluated at the same institution. Eligible participants will be consecutively enrolled from the relevant clinical units during the study period. The three groups will constitute the source population for the comparative evaluation of blood and urine phoenixin levels and their relationship with pain and burn-related clinical characteristics.

Eligibility criteria

Inclusion Criteria:

  • Inclusion Criteria:
  • Children younger than 18 years of age who have not entered puberty.
  • Both sexes are eligible.
  • Written for participation in the study obtained from a parent or legal guardian.
  • For the acute burn group: children with second-degree burns who are being followed in the burn intensive care unit.
  • For the chronic burn group: a history of burn injury, with at least three months elapsed since the burn.
  • For the control group: no history of burn injury and no acute pain at the time of assessment.

Exclusion Criteria:

  • Neurological, endocrine, or active systemic inflammatory disease that may affect phoenixin (PNX) levels or pain assessment.
  • Having entered puberty.
  • Inability to obtain the biological samples required for the study.
  • Lack of written informed consent from a parent or legal guardian.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
87 participants (estimated)
Patient registry
No

Groups and cohorts

  • 1. Acute Burn Group

    Children with second-degree burn injuries who are in the acute burn period and have pain at the time of assessment. Blood and urine samples will be collected for measurement of phoenixin levels, and pain intensity will be assessed using age-appropriate validated pain scales. Burn characteristics, including total body surface area (TBSA), will also be recorded.

  • 2. Chronic Burn Group

    Children with a history of burn injury at least three months previously who have completed the acute burn and procedural pain period. Blood and urine samples will be collected for measurement of phoenixin levels.

  • 3. Healthy Control Group

    Age-similar children without a history of burn injury or acute pain. Blood and urine samples will be collected for measurement of phoenixin levels.

06

What researchers measure

Primary outcomes

  1. Difference in Blood and Urine Phoenixin Levels Among the Study Groups

    Blood and urine phoenixin (PNX) concentrations measured by enzyme-linked immunosorbent assay (ELISA) will be compared among the acute burn, chronic burn, and healthy control groups.

    Time frame: At the time of study enrollment

  2. Association Between Phoenixin Levels and Pain Intensity in the Acute Burn Group

    The association between blood and urine PNX concentrations and clinical pain intensity will be evaluated in children with acute burns. Pain intensity will be assessed using an age-appropriate validated pain assessment scale (FLACC or VAS, as applicable).

    Time frame: At the time of study enrollment

Secondary outcomes

  1. Association Between Blood and Urine Phoenixin Levels

    The association between blood and urine phoenixin (PNX) concentrations will be evaluated to determine whether PNX levels measured in urine are correlated with those measured in blood.

    Time frame: At the time of study enrollment

  2. Association Between Phoenixin Levels and Total Body Surface Area

    The association between blood and urine PNX concentrations and total body surface area (TBSA) affected by burn injury will be evaluated in pediatric burn patients.

    Time frame: At the time of study enrollment

  3. Association Between Phoenixin Levels and Demographic and Clinical Characteristics

    Associations between blood and urine PNX concentrations and demographic and clinical characteristics, including age, sex, and body mass index (BMI), will be evaluated.

    Time frame: At the time of study enrollment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for May 2027, 7 months later.

Of 72 non-industry observational studies under Acute Pain, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 41. This study's planned 7 months is below that.

Counting every sponsor, half of 74 studies reached it within 15 months; a quarter within 5 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
May 31, 2027
CompletionEst.
Oct 1, 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07858409
Collaborators
Firat University
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
May 31, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Feyza SEVER, Assoc Prof
Contact
feyza.altay@hotmail.com
+903125526000
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion